Comerica Bank Purchases 789 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Comerica Bank increased its holdings in Regeneron Pharmaceuticals by 5.6% by acquiring 789 shares, bringing its total shares to 14,976, valued at approximately $9.5 million.
• Regeneron Pharmaceuticals reported an earnings per share (EPS) of $12.89 for the latest quarter, significantly exceeding analysts' expectations of $8.43, with a year-over-year revenue increase of 3.6%.
• The company declared a quarterly dividend of $0.88 per share, with a payout ratio of 8.87%, reflecting its commitment to returning value to shareholders.

Comerica Bank boosted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 5.6% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 14,976 shares of the biopharmaceutical company's stock after acquiring an additional 789 shares during the period. Comerica Bank's holdings in Regeneron Pharmaceuticals were worth $9,498,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Pinney & Scofield Inc. bought a new stake in Regeneron Pharmaceuticals in the 4th quarter worth $25,000. E Fund Management Hong Kong Co. Ltd. grew its holdings in Regeneron Pharmaceuticals by 344.4% in the 1st quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock worth $25,000 after acquiring an additional 31 shares during the last quarter. Costello Asset Management INC bought a new stake in Regeneron Pharmaceuticals in the 1st quarter worth $27,000. Tompkins Financial Corp bought a new stake in shares of Regeneron Pharmaceuticals during the 1st quarter valued at about $32,000. Finally, Curat Global LLC bought a new stake in shares of Regeneron Pharmaceuticals during the 1st quarter valued at about $32,000. Institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Trading Up 2.7%

NASDAQ:REGN opened at $587.65 on Wednesday. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.60 and a quick ratio of 3.72. The company's 50-day simple moving average is $553.05 and its 200 day simple moving average is $589.45. The firm has a market capitalization of $62.28 billion, a P/E ratio of 14.81, a PEG ratio of 1.91 and a beta of 0.33.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings data on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, topping the consensus estimate of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The business had revenue of $3,675,600 billion for the quarter, compared to analyst estimates of $3.30 billion. During the same quarter in the previous year, the firm posted $11.56 earnings per share. Regeneron Pharmaceuticals's quarterly revenue was up 3.6% on a year-over-year basis. As a group, analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 3rd. Investors of record on Monday, August 18th will be paid a dividend of $0.88 per share. The ex-dividend date of this dividend is Monday, August 18th. This represents a $3.52 annualized dividend and a yield of 0.6%. Regeneron Pharmaceuticals's payout ratio is presently 8.87%.

Analyst Upgrades and Downgrades

REGN has been the topic of a number of research reports. Guggenheim lifted their target price on shares of Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the company a "buy" rating in a research note on Friday, August 1st. Wall Street Zen lowered shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Thursday, May 1st. The Goldman Sachs Group cut their target price on shares of Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating on the stock in a research note on Wednesday, April 30th. BMO Capital Markets lifted their target price on shares of Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the company an "outperform" rating in a research note on Monday, August 4th. Finally, Citigroup reaffirmed a "buy" rating and set a $650.00 target price on shares of Regeneron Pharmaceuticals in a research note on Friday, August 1st. Three research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $829.65.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.